Clozapine Causes Metformin-Resistant Prediabetes/Diabetes, which is Associated with Poor Clinical Efficacy in Patients with Early TreatmentResistant Schizophren
Received Date: Jan 03, 2023 / Published Date: Jan 30, 2023
Abstract
Two distinct subtypes of treatment-resistant schizophrenia (TRS) area unit recently reported, further as earlytreatment resistance (E-TR) and late-treatment resistance (L-TR). This study was to assess clozapine-induced metformin-resistant prediabetes/diabetes and its correlation with clinical effectiveness in schizophrenia E-TR subtype. The incidence of clozapine-induced metformin-resistant prediabetes/diabetes was considerably high in schizophrenia early-treatment resistance (E-TR) subtype. Clozapine-induced metformin-resistantprediabetes/ diabetes represented degree freelance risk issue that adversely affected the clinical effectiveness of tranquilizer for schizophrenia E-TR subtype. Switch to tranquilizer strategy need to be reconsidered at intervals the treatment of patients with schizophrenia E-TR subtype. Given the high incidence of metformin-resistant clozapine-induced prediabetes/diabetes, the viability of manner interventions to prevent clozapine-induced prediabetes/diabetes in patients with schizophrenia E-TR subtype need to be assessed in future studies
Citation: Sanchez P (2023) Clozapine Causes Metformin-Resistant Prediabetes/Diabetes, which is Associated with Poor Clinical Efficacy in Patients with EarlyTreatment-Resistant Schizophrenia. J Clin Diabetes 7: 161. Doi: 10.4172/jcds.1000161
Copyright: © 2023 Sanchez P. This is an open-access article distributed underthe terms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.
Share This Article
Recommended Journals
天美传媒 Access Journals
Article Tools
Article Usage
- Total views: 1023
- [From(publication date): 0-2023 - Jan 11, 2025]
- Breakdown by view type
- HTML page views: 823
- PDF downloads: 200